Allergan PLC (AGN) Shares Bought by Montag & Caldwell LLC
Montag & Caldwell LLC increased its stake in shares of Allergan PLC (NYSE:AGN) by 16.2% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 687,035 shares of the company’s stock after buying an additional 95,951 shares during the period. Allergan PLC comprises approximately 3.2% of Montag & Caldwell LLC’s holdings, making the stock its 13th largest position. Montag & Caldwell LLC owned approximately 0.17% of Allergan PLC worth $158,767,000 at the end of the most recent reporting period.
Several other institutional investors also recently made changes to their positions in the stock. Barnett & Company Inc. bought a new position in shares of Allergan PLC during the first quarter valued at about $111,000. Livingston Group Asset Management CO operating as Southport Capital Management bought a new position in shares of Allergan PLC during the second quarter valued at about $125,000. Trust Co. of Vermont boosted its position in shares of Allergan PLC by 19.5% in the second quarter. Trust Co. of Vermont now owns 545 shares of the company’s stock valued at $126,000 after buying an additional 89 shares in the last quarter. Ropes Wealth Advisors LLC boosted its position in shares of Allergan PLC by 13.2% in the first quarter. Ropes Wealth Advisors LLC now owns 497 shares of the company’s stock valued at $133,000 after buying an additional 58 shares in the last quarter. Finally, Integrated Investment Consultants LLC boosted its position in shares of Allergan PLC by 35.2% in the second quarter. Integrated Investment Consultants LLC now owns 592 shares of the company’s stock valued at $137,000 after buying an additional 154 shares in the last quarter. Institutional investors own 85.19% of the company’s stock.
Shares of Allergan PLC (NYSE:AGN) traded up 1.24% during trading on Tuesday, hitting $235.63. 2,504,125 shares of the company were exchanged. The firm has a market capitalization of $93.30 billion, a PE ratio of 22.43 and a beta of 0.81. The firm’s 50-day moving average price is $241.85 and its 200 day moving average price is $239.87. Allergan PLC has a 12 month low of $195.50 and a 12 month high of $322.68.
Allergan PLC (NYSE:AGN) last released its earnings results on Monday, August 8th. The company reported $3.35 EPS for the quarter, topping analysts’ consensus estimates of $3.34 by $0.01. The company earned $3.68 billion during the quarter, compared to analysts’ expectations of $4.10 billion. Allergan PLC had a net margin of 28.06% and a return on equity of 7.67%. Allergan PLC’s revenue for the quarter was up 1.0% on a year-over-year basis. During the same period last year, the business earned $4.41 EPS. On average, equities research analysts expect that Allergan PLC will post $14.00 earnings per share for the current fiscal year.
AGN has been the topic of several research reports. Goldman Sachs Group Inc. reissued a “buy” rating on shares of Allergan PLC in a research note on Wednesday, July 6th. Leerink Swann boosted their price objective on shares of Allergan PLC from $272.00 to $294.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 27th. JPMorgan Chase & Co. set a $325.00 price objective on shares of Allergan PLC and gave the stock a “buy” rating in a research note on Friday, August 5th. Zacks Investment Research lowered shares of Allergan PLC from a “buy” rating to a “hold” rating in a research note on Tuesday, July 26th. Finally, Vetr raised shares of Allergan PLC from a “buy” rating to a “strong-buy” rating and set a $285.60 price objective on the stock in a research note on Monday, August 1st. Six equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Allergan PLC presently has an average rating of “Buy” and a consensus price target of $300.64.
Allergan PLC Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Stock Ratings for Allergan PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC and related stocks with our FREE daily email newsletter.